New hope for brain cancer: FAU awarded grants for glioblastoma treatment
Grant and Award Announcement
Updates every hour. Last Updated: 1-Jul-2025 09:10 ET (1-Jul-2025 13:10 GMT/UTC)
Researchers are pioneering a new approach to treating glioblastoma by targeting the gene MBLAC1 for the first time. This gene regulates copper levels and influences mitochondrial function—both essential to cancer cell survival. Disrupting MBLAC1 could impair tumor growth and open a new path for therapy. The study breaks new ground by revealing a molecular pathway that drives cancer through a gene tied to copper regulation and glioblastoma risk. Glioblastoma is a highly aggressive brain cancer with one of the highest mortality rates.
AI models have the potential not only to spot pancreatic cancer at an early stage, but also to predict the deadly disease’s prognosis, say scientists
Senescent cells, which are damaged and inflammatory, contribute significantly to ageing. Researchers at the Max Planck Institute for Biology of Ageing have found that worms can enter a senescent-like state, similar to that observed in mammals. This discovery provides a simple yet powerful model to study senescence at the whole organism level, enabling the identification of new ways to prevent or reverse senescence. These findings hold promise for developing therapies targeting age-related conditions and cancer dormancy.
Northwestern Medicine scientists have developed an AI tool called iSeg that not only matches doctors in accurately outlining lung tumors on CT scans but can also identify areas that some doctors may miss, reports a large new study.
A unique luminescent probe uses terbium, a rare earth metal, to sense the presence of an enzyme called β-glucuronidase, a biomarker for liver cancer
Scientists from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, have developed a novel ultrasound-driven therapy that activates dormant cancer drugs directly inside tumors. By combining low-intensity ultrasound with specially designed nanoparticles, the team achieved a 99% tumor suppression rate and 66.7% cure rate in mice. This non-invasive approach minimizes side effects and could revolutionize targeted cancer treatment.
• These findings emphasize the need to integrate age, pre-neoadjuvant CEA and NLR levels, PD-1 expression, and CT-detected mediastinal lymph node changes into postoperative management strategies.
• Clinical practices should adapt to routinely evaluate these parameters to better stratify patients’ risks and personalize postoperative care plans.
New urine-based tumor DNA (utDNA) test may help predict the recurrence of bladder cancer in high-risk patients and more personalized cancer treatments.